ZA200202246B - Monoclonal Antibody 3F1H10 Neutralising VHSV (Haemorrhagic Septicaemia VI). - Google Patents
Monoclonal Antibody 3F1H10 Neutralising VHSV (Haemorrhagic Septicaemia VI). Download PDFInfo
- Publication number
- ZA200202246B ZA200202246B ZA200202246A ZA200202246A ZA200202246B ZA 200202246 B ZA200202246 B ZA 200202246B ZA 200202246 A ZA200202246 A ZA 200202246A ZA 200202246 A ZA200202246 A ZA 200202246A ZA 200202246 B ZA200202246 B ZA 200202246B
- Authority
- ZA
- South Africa
- Prior art keywords
- construct
- antibody
- antibody molecule
- fish
- gene
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title description 11
- 208000032969 Hemorrhagic Septicemia Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 241000711825 Viral hemorrhagic septicemia virus Species 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 21
- 244000052769 pathogen Species 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 230000001717 pathogenic effect Effects 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 239000013566 allergen Substances 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 9
- 230000001681 protective effect Effects 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims description 7
- 230000002458 infectious effect Effects 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 208000030961 allergic reaction Diseases 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 231100000167 toxic agent Toxicity 0.000 claims description 4
- 239000003440 toxic substance Substances 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000002435 venom Substances 0.000 claims description 2
- 231100000611 venom Toxicity 0.000 claims description 2
- 210000001048 venom Anatomy 0.000 claims description 2
- 241001327682 Oncorhynchus mykiss irideus Species 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 230000007096 poisonous effect Effects 0.000 claims 1
- 235000019688 fish Nutrition 0.000 description 55
- 241000251468 Actinopterygii Species 0.000 description 47
- 239000013612 plasmid Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 24
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 241000277331 Salmonidae Species 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 206010039509 Scab Diseases 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000725619 Dengue virus Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000277275 Oncorhynchus mykiss Species 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000589972 Borrelia sp. Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000702626 Infectious bursal disease virus Species 0.000 description 1
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 description 1
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 1
- 241000546112 Infectious salmon anemia virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000186813 Renibacterium Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- JXVIIQLNUPXOII-UHFFFAOYSA-N Siduron Chemical compound CC1CCCCC1NC(=O)NC1=CC=CC=C1 JXVIIQLNUPXOII-UHFFFAOYSA-N 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000725110 Vilyuisk human encephalomyelitis virus Species 0.000 description 1
- 208000001449 Viral Hemorrhagic Septicemia Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 206010035485 plasmacytosis Diseases 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 101150069452 z gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199901329 | 1999-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200202246B true ZA200202246B (en) | 2002-11-27 |
Family
ID=8103646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200202246A ZA200202246B (en) | 1999-09-20 | 2002-03-20 | Monoclonal Antibody 3F1H10 Neutralising VHSV (Haemorrhagic Septicaemia VI). |
Country Status (5)
Country | Link |
---|---|
US (2) | US7265095B1 (de) |
EP (1) | EP1218507A1 (de) |
AU (1) | AU782805B2 (de) |
WO (1) | WO2001021800A1 (de) |
ZA (1) | ZA200202246B (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2777920A1 (en) * | 2009-10-16 | 2011-04-21 | National University Corporation Tokyo University Of Marine Science And T Echnology | Aptamer capable of binding to viral hemorrhagic septicemia virus |
CN103995124B (zh) * | 2014-04-14 | 2017-01-18 | 杭州贝尔塔生物技术有限公司 | 检测猪唾液中伪狂犬病毒gE蛋白特异性抗体的方法 |
CN103995125B (zh) * | 2014-04-14 | 2017-01-04 | 杭州贝尔塔生物技术有限公司 | 检测猪唾液中伪狂犬病毒gB蛋白特异性抗体的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US5614611A (en) * | 1987-12-31 | 1997-03-25 | Tanox Biosystems, Inc. | Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils |
CA2137558A1 (en) * | 1992-07-17 | 1994-02-03 | Wayne A. Marasco | Method of intracellular binding of target molecules |
WO1996037234A1 (en) * | 1995-05-23 | 1996-11-28 | Thomas Jefferson University | Intracellular immunization |
AU1256099A (en) | 1997-11-13 | 1999-06-07 | University Of Manitoba | Method and kit for determining severe inflammatory reactions to mosquito bites |
-
2000
- 2000-09-20 AU AU76730/00A patent/AU782805B2/en not_active Ceased
- 2000-09-20 EP EP00966284A patent/EP1218507A1/de not_active Ceased
- 2000-09-20 US US10/088,780 patent/US7265095B1/en not_active Expired - Fee Related
- 2000-09-20 WO PCT/GB2000/003605 patent/WO2001021800A1/en active Search and Examination
-
2002
- 2002-03-20 ZA ZA200202246A patent/ZA200202246B/en unknown
-
2007
- 2007-07-27 US US11/829,201 patent/US20080085868A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU7673000A (en) | 2001-04-24 |
US7265095B1 (en) | 2007-09-04 |
WO2001021800A1 (en) | 2001-03-29 |
EP1218507A1 (de) | 2002-07-03 |
US20080085868A1 (en) | 2008-04-10 |
AU782805B2 (en) | 2005-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230048561A1 (en) | Modified Antibody | |
JP3786695B2 (ja) | 修飾した抗原性免疾グロブリンによるt細胞の活性化 | |
SA96170384B1 (ar) | وطرق تحضيرها واستخداماتها العلاجية (rsv) الاجسام المضادة المعادلة البشرية احادية النسيلة ذات الالفة العالية المختصة ببروتين - ف للفيروس المخلوي التنفسي | |
KR102061352B1 (ko) | 아넥신 1 항체 | |
JP2010104375A (ja) | 粥状動脈硬化の治療用のペプチドベースの受動免疫療法 | |
NZ516264A (en) | Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer | |
CA2607771A1 (en) | Humanized anti-venezuelan equine encephalitis virus recombinant antibody | |
JP2020072685A (ja) | クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンa及びトキシンbに対する四重特異性の八量体型結合剤及び抗体 | |
US20230212231A1 (en) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes | |
US20080085868A1 (en) | Monoclonal Antibody 3F1H10 Neutralising VHSV (Viral Haemorrhagic Septicaemia Virus) | |
US9321834B2 (en) | Anti-malarial compositions | |
WO2014043215A1 (en) | Bi-specifc diabodies for masking and targeting vaccines | |
US20040052773A1 (en) | Production of multi-chain protein from muscle | |
CN116262785A (zh) | 抗抑制素抗体及其应用 | |
JPH07203974A (ja) | 癌特異的ムチンを認識する抗体の遺伝子断片等 | |
KR100467706B1 (ko) | B형 간염 바이러스의 표면 항원에 대한 인간항체 | |
Froyen et al. | Bacterial expression of a single-chain antibody fragment (scFv) that neutralizes the biological activity of human interferon | |
Lamarre et al. | A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice | |
CN110087677A (zh) | 靶向埃博拉病毒糖蛋白内部融合环的广泛中和抗体 | |
JP2024518151A (ja) | Covid-19および新興変異株の処置および予防のための抗体 | |
CN116655778A (zh) | 抗sars-cov-2-刺突蛋白抗体和抗原结合片段 | |
US7011835B1 (en) | Targeted destruction of pests | |
WO2001058955A1 (en) | Targeted destruction of pests | |
JP3908257B2 (ja) | ニワトリ型モノクローナル抗体用のオリゴヌクレオチド | |
KR20040084875A (ko) | B형 간염 바이러스의 표면 항원에 대한 인간항체의가변영역을 삽입할 수 있는 항체발현 플라스미드 |